Emergent Biosolutions EBS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $676.8M-8.9% | $742.9M-5.8% | $788.9M-7.4% | $851.6M-11.8% | $965.4M-7.5% | ||
| $309.7M-5.1% | $326.2M-9.2% | $359.3M-9.3% | $396M-36.7% | $625.2M-8.2% | ||
| $367.1M-11.9% | $416.7M-3.0% | $429.6M-5.7% | $455.6M+33.9% | $340.2M-6.1% | ||
| 54.2%-1.9pp | 56.1%+1.6pp | 54.5%+1.0pp | 53.5%+18.3pp | 35.2%+0.5pp | ||
| $48.6M-8.6% | $53.2M+6.0% | $50.2M-0.6% | $50.5M-28.6% | $70.7M0.0% | ||
| $180.3M-3.1% | $186.1M-5.0% | $195.8M-16.1% | $233.5M-15.3% | $275.7M-10.5% | ||
| $616.1M-4.2% | $642.8M-4.1% | $670.4M-10.0% | $745.1M-30.0% | $1.06B-7.7% | ||
| —— | —— | $118.5M+11.3% | $106.5M+208% | -$98.6M+9.3% | ||
| $55.6M-6.2% | $59.3M-0.2% | $59.4M+13.1% | $52.5M-14.5% | $61.4M-13.5% | ||
| -$57.2M-231% | -$17.3M-37.3% | -$12.6M-115% | $84.2M+132% | $36.3M+206% | ||
| —— | —— | $105.9M-44.5% | $190.7M+406% | -$62.3M+56.4% | ||
| $12.1M-59.9% | $30.2M+0.7% | $30M-41.4% | $51.2M-26.1% | $69.3M+45.3% | ||
| —— | —— | $75.9M-45.6% | $139.5M+206% | -$131.6M+31.0% | ||
| —— | —— | $1.31-46.7% | $2.46+191% | -$2.70+27.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Emergent Biosolutions's revenue?
- Emergent Biosolutions (EBS) generated $676.8M in revenue over the trailing twelve months, down 29.9% year over year.
- Is Emergent Biosolutions profitable?
- Emergent Biosolutions reported $114.0M in net income over the trailing twelve months, a 9.6% net margin.
- What are Emergent Biosolutions's profit margins?
- Gross margin is 54.2% and operating margin is 15.0%, with a 9.6% net margin.
- What is Emergent Biosolutions's earnings per share?
- Emergent Biosolutions's diluted EPS over the trailing twelve months is $1.95.
- Where does Emergent Biosolutions's income statement data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
